JP2022548943A5 - - Google Patents
Info
- Publication number
- JP2022548943A5 JP2022548943A5 JP2022517799A JP2022517799A JP2022548943A5 JP 2022548943 A5 JP2022548943 A5 JP 2022548943A5 JP 2022517799 A JP2022517799 A JP 2022517799A JP 2022517799 A JP2022517799 A JP 2022517799A JP 2022548943 A5 JP2022548943 A5 JP 2022548943A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- derived
- cell
- car
- bcma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025211240A JP2026041849A (ja) | 2019-09-25 | 2025-12-01 | 複数標的化エフェクター細胞およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906046P | 2019-09-25 | 2019-09-25 | |
| US62/906,046 | 2019-09-25 | ||
| US201962944187P | 2019-12-05 | 2019-12-05 | |
| US62/944,187 | 2019-12-05 | ||
| PCT/US2020/052890 WO2021062281A2 (en) | 2019-09-25 | 2020-09-25 | Multi-targeting effector cells and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025211240A Division JP2026041849A (ja) | 2019-09-25 | 2025-12-01 | 複数標的化エフェクター細胞およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548943A JP2022548943A (ja) | 2022-11-22 |
| JP2022548943A5 true JP2022548943A5 (https=) | 2023-10-03 |
Family
ID=75166460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517799A Pending JP2022548943A (ja) | 2019-09-25 | 2020-09-25 | 複数標的化エフェクター細胞およびその使用 |
| JP2025211240A Pending JP2026041849A (ja) | 2019-09-25 | 2025-12-01 | 複数標的化エフェクター細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025211240A Pending JP2026041849A (ja) | 2019-09-25 | 2025-12-01 | 複数標的化エフェクター細胞およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378831A1 (https=) |
| EP (1) | EP4034638A4 (https=) |
| JP (2) | JP2022548943A (https=) |
| KR (1) | KR20220085779A (https=) |
| CN (1) | CN114867846A (https=) |
| AU (1) | AU2020353166A1 (https=) |
| BR (1) | BR112022005602A2 (https=) |
| CA (1) | CA3149585A1 (https=) |
| IL (1) | IL291484A (https=) |
| MX (1) | MX2022003414A (https=) |
| WO (1) | WO2021062281A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP4097220A4 (en) * | 2020-01-30 | 2024-03-20 | ImmunityBio, Inc. | ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| JP2024522756A (ja) * | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| US20240316102A1 (en) | 2021-07-01 | 2024-09-26 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| GB202110363D0 (en) * | 2021-07-19 | 2021-09-01 | Celyad S A | NKG2D CAR cells expressing IL-18 for adoptive cell therapy |
| CN117835993A (zh) * | 2021-08-18 | 2024-04-05 | 菲特治疗公司 | 作为单一疗法以及与抗体组合的现成的iPSC衍生的CAR-NK细胞 |
| AU2022371471A1 (en) * | 2021-10-20 | 2024-05-02 | Fate Therapeutics, Inc. | Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors |
| KR20240102994A (ko) * | 2021-11-08 | 2024-07-03 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양의 유비쿼터스 표적화를 향상시키는 조작된 이펙터 세포 및 방법 |
| US20250228943A1 (en) * | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| JP2025525439A (ja) | 2022-06-30 | 2025-08-05 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法 |
| WO2024068617A1 (en) * | 2022-09-26 | 2024-04-04 | Institut Curie | Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy |
| CN120092090A (zh) * | 2022-11-07 | 2025-06-03 | 上海先博生物科技有限公司 | 工程化嵌合抗原受体免疫细胞及其应用 |
| CN121586777A (zh) * | 2023-07-26 | 2026-02-27 | 上海邦耀生物医药有限公司 | 用于治疗疾病的方法和组合物 |
| WO2025109493A1 (en) * | 2023-11-21 | 2025-05-30 | National University Of Singapore | Chimeric Receptors with Binding Capacity for Antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| KR102526945B1 (ko) * | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN117721084A (zh) * | 2017-10-12 | 2024-03-19 | 美商生物细胞基因治疗有限公司 | 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法 |
| JP2021505131A (ja) * | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| IL316257A (en) * | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
-
2020
- 2020-09-25 MX MX2022003414A patent/MX2022003414A/es unknown
- 2020-09-25 AU AU2020353166A patent/AU2020353166A1/en active Pending
- 2020-09-25 CN CN202080080349.4A patent/CN114867846A/zh active Pending
- 2020-09-25 KR KR1020227013077A patent/KR20220085779A/ko active Pending
- 2020-09-25 BR BR112022005602A patent/BR112022005602A2/pt unknown
- 2020-09-25 CA CA3149585A patent/CA3149585A1/en active Pending
- 2020-09-25 EP EP20869750.8A patent/EP4034638A4/en active Pending
- 2020-09-25 JP JP2022517799A patent/JP2022548943A/ja active Pending
- 2020-09-25 US US17/762,693 patent/US20220378831A1/en active Pending
- 2020-09-25 WO PCT/US2020/052890 patent/WO2021062281A2/en not_active Ceased
-
2022
- 2022-03-17 IL IL291484A patent/IL291484A/en unknown
-
2025
- 2025-12-01 JP JP2025211240A patent/JP2026041849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548943A5 (https=) | ||
| JP2021505131A5 (https=) | ||
| JP2022541441A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| JP2022510207A5 (https=) | ||
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2021519061A5 (https=) | ||
| JP2023505206A5 (https=) | ||
| JP2023530704A5 (https=) | ||
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| JP2023548467A5 (https=) | ||
| JP2023549098A5 (https=) | ||
| JP2023548829A5 (https=) | ||
| CN114761425A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2025108510A (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| JP2023545992A5 (https=) | ||
| JP2022510207A (ja) | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 | |
| RS62870B1 (sr) | Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe | |
| JP2023029624A (ja) | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 | |
| EP3029137B1 (en) | Genetic modified pluri- or multipotent stem cells and uses thereof | |
| JP2024533375A5 (https=) | ||
| KR102883294B1 (ko) | 조작된 iPSC 및 보강된 면역 효과기 세포 | |
| AU2021338819A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| JP7701453B2 (ja) | 固形腫瘍標的化骨格を有する細胞及びその使用 | |
| JP2024515920A5 (https=) |